Anúncio
Anúncio
SABS
SAB Biotherapeutics, Inc. Common Stock
3.67
USDPatrocinado
-0.19
-4.92%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
3.81
+0.14
+3.81%
Relatórios de Lucros SABS
Rácio de surpresa positiva
SABS separação 11 de 17 últimas estimativas.
65%
Próximo Relatório
Data do Próximo Relatório
30 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.18
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/+20.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-100.00%
/-85.25%
SAB Biotherapeutics, Inc. Common Stock earnings per share and revenue
On 14 de nov. de 2025, SABS reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.51 USD, resulting in a 70.94% surprise. Revenue reached --, compared to an expected 102.00 mil, with a -100.00% difference. The market reacted with a +4.52% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analistas forecast an EPS of -0.18 USD, with revenue projected to reach -- USD, implying an aumentar of 20.00% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were SAB Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, SAB Biotherapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 70.94%, and revenue of $0.00, -100% below expectations.
How did the market react to SAB Biotherapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 4.52%, changed from $3.10 before the earnings release to $3.24 the day after.
When is SAB Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30 de mar. de 2026.
What are the forecasts for SAB Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 9
analistas, SAB Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio